$ABVC
ABVC BIOPHARMA, INC. Stock $abvc

$abvc Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000121390024022235 Filed on March 13, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$1.205K	$2.170K	$152.4K
YoY Change	-99.06%	-99.63%	-84.28%
Cost Of Revenue	$277.00	$139.2K	$302.0K
YoY Change	-99.54%	-47.55%	5.45%
Gross Profit	$928.00	-$137.0K	-$149.6K
YoY Change	-98.64%	-142.35%	-121.89%
Gross Profit Margin	77.01%	-6315.21%	-98.15%
Selling, General & Admin	$831.3K	$1.752M	$5.368M
YoY Change	-34.69%	-10.63%	-11.52%
% of Gross Profit	89575.11%
Research & Development	$69.07K	$72.19K	$1.063M
YoY Change	-79.38%	-95.17%	-60.54%
% of Gross Profit	7442.46%
Depreciation & Amortization	$1.286K	$7.580K	$28.53K
YoY Change	-80.19%	17.7%	19.88%
% of Gross Profit	138.58%
Operating Expenses	$3.445M	$1.825M	$8.067M
YoY Change	74.52%	-47.21%	-48.94%
Operating Profit	-$3.444M	-$1.962M	-$8.217M
YoY Change	80.7%	-37.39%	-45.64%
Interest Expense	$684.7K	-$1.209M	$2.493M
YoY Change	1108.34%	237.09%	748.17%
% of Operating Profit
Other Income/Expense, Net	-$536.6K	$16.56K	-$2.438M
YoY Change	-6093.18%	-74.07%	509.16%
Pretax Income	-$3.981M	-$3.154M	-$10.65M
YoY Change	109.83%	-10.84%	-31.33%
Income Tax		$175.3K	$256.0K
% Of Pretax Income
Net Earnings	-$3.933M	-$3.111M	-$10.52M
YoY Change	115.66%	-36.04%	-35.97%
Net Earnings / Revenue	-326388.05%	-143360.83%	-6898.68%
Basic Earnings Per Share	-$0.40		-$2.43
Diluted Earnings Per Share	-$0.40	-$0.47	-$2.43
COMMON SHARES
Basic Shares Outstanding	10.56M shares	7.232M shares	4.336M shares
Diluted Shares Outstanding	9.736M shares		4.336M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$106.4K	$139.5K	$139.5K
YoY Change	-91.23%	-13.4%	-13.4%
Cash & Equivalents	$30.49K	$60.16K	$60.16K
Short-Term Investments	$75.92K	$79.31K	$79.31K
Other Short-Term Assets	$788.1K	$757.7K	$757.7K
YoY Change	-21.56%	-47.99%	-47.99%
Inventory
Prepaid Expenses
Receivables	$1.530K	$1.530K	$11.99K
Other Receivables	$887.9K	$747.6K	$747.6K
Total Short-Term Assets	$1.794M	$1.657M	$1.657M
YoY Change	-48.44%	-44.54%	-44.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.949M	$7.969M	$8.779M
YoY Change	1290.74%	1288.43%	405.93%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$2.475M	$2.528M	$2.528M
YoY Change	191.17%	200.18%	200.18%
Other Assets	$1.411M	$1.416M	$1.416M
YoY Change	-59.56%	-67.0%	-67.0%
Total Long-Term Assets	$12.67M	$12.84M	$12.84M
YoY Change	74.59%	86.89%	86.89%
TOTAL ASSETS
Total Short-Term Assets	$1.794M	$1.657M	$1.657M
Total Long-Term Assets	$12.67M	$12.84M	$12.84M
Total Assets	$14.46M	$14.49M	$14.49M
YoY Change	34.7%	47.05%	47.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$3.513M	$3.696M	$4.098M
YoY Change	27.13%	27.04%	24.99%
Deferred Revenue	$79.50K	$79.50K
YoY Change		623.71%
Short-Term Debt	$860.8K	$899.3K	$899.3K
YoY Change	-4.57%	-52.51%	-52.51%
Long-Term Debt Due	$842.6K	$569.5K	$569.5K
YoY Change
Total Short-Term Liabilities	$6.634M	$5.932M	$5.932M
YoY Change	30.71%	1.94%	1.94%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%
Other Long-Term Liabilities	$339.8K	$429.1K	$429.1K
YoY Change	-52.73%	-46.34%	-46.34%
Total Long-Term Liabilities	$339.8K	$429.1K	$429.1K
YoY Change	-91.34%	-46.34%	-46.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.634M	$5.932M	$5.932M
Total Long-Term Liabilities	$339.8K	$429.1K	$429.1K
Total Liabilities	$6.973M	$6.362M	$6.105M
YoY Change	-22.52%	-3.89%	-9.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$69.35M	-$65.42M
YoY Change	22.26%	19.15%
Common Stock	$10.70K	$7.940K
YoY Change	-67.66%	-75.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$8.902M	$8.902M
YoY Change	-2.17%	-2.18%
Treasury Stock Shares
Shareholders Equity	$7.792M	$8.388M	$8.388M
YoY Change
Total Liabilities & Shareholders Equity	$14.46M	$14.49M	$14.49M
YoY Change	34.7%	47.05%	47.05%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$3.933M	-$3.111M	-$10.52M
YoY Change	115.66%	-36.04%	-35.97%
Depreciation, Depletion And Amortization	$1.286K	$7.580K	$28.53K
YoY Change	-80.19%	17.7%	19.88%
Cash From Operating Activities	-$473.2K	-$479.5K	-$4.236M
YoY Change	-68.41%	3.99%	-42.75%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$21.20K
YoY Change		-100.0%	-82.29%
Acquisitions
YoY Change
Other Investing Activities		$154.2K	-$339.0K
YoY Change		-285.3%	-78.84%
Cash From Investing Activities		$154.2K	-$360.2K
YoY Change		-285.12%	-79.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$1.050M
YoY Change			-71.34%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$676.2K	87.42K	$3.919M
YoY Change	-69.36%	-134.49%	-2.37%
NET CHANGE
Cash From Operating Activities	-$473.2K	-479.5K	-$4.236M
Cash From Investing Activities		154.2K	-$360.2K
Cash From Financing Activities	$676.2K	87.42K	$3.919M
Net Change In Cash	-$57.78K	-237.9K	-$674.9K
YoY Change	-114.44%	-70.19%	-86.95%
FREE CASH FLOW
Cash From Operating Activities	-$473.2K	-$479.5K	-$4.236M
Capital Expenditures		$0.00	$21.20K
Free Cash Flow		-$479.5K	-$4.257M
YoY Change		3.97%	-43.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40700
CY2023	dei	Entity Registrant Name EntityRegistrantName	ABVC BioPharma, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-0014658
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	44370 Old Warm Springs Blvd.
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Fremont
CY2023	dei	Entity Address Country EntityAddressCountry	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94538
CY2023	dei	City Area Code CityAreaCode	(510)
CY2023	dei	Local Phone Number LocalPhoneNumber	-668-0881
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	ABVC
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	5200000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10560421	shares
CY2023	dei	Auditor Name AuditorName	WWC, P.C.
CY2023	dei	Auditor Firm AuditorFirmId	1171
CY2023	dei	Auditor Location AuditorLocation	San Mateo, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60155	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85265	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	656625	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	1306463	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1530	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	98325	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	79312	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	75797	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	101051	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	150235	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1656709	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2987247	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7969278	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	573978	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	809283	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1161141	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	2527740	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	842070	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	117110	usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	78789	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	135135	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	62442	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	58838	usd
CY2023Q4	abvc	Prepayment For Longterm Investments Noncurrent PrepaymentForLongtermInvestmentsNoncurrent	1274842	usd
CY2022Q4	abvc	Prepayment For Longterm Investments Noncurrent PrepaymentForLongtermInvestmentsNoncurrent	2838578	usd
CY2023Q4	us-gaap	Assets Assets	14492599	usd
CY2022Q4	us-gaap	Assets Assets	9579574	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	899250	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	1893750	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3696380	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2909587	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	79500	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10985	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	112946	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	401826	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	369314	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	569456	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5932490	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5543628	usd
CY2023Q4	us-gaap	Security Deposit Liability SecurityDepositLiability	21680	usd
CY2022Q4	us-gaap	Security Deposit Liability SecurityDepositLiability	7980	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	407457	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	791827	usd
CY2023Q4	us-gaap	Liabilities Liabilities	6361627	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6343435	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7940298	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7940298	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3286190	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3286190	shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	82636966	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	67937050	usd
CY2023Q4	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	451480	usd
CY2022Q4	us-gaap	Stockholders Equity Note Subscriptions Receivable StockholdersEquityNoteSubscriptionsReceivable	1354440	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65420095	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-54904439	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	516387	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	517128	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	8901668	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	9100000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	8388050	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3098585	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-257078	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	137554	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8130972	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3236139	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14492599	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9579574	usd
CY2023	us-gaap	Revenues Revenues	152430	usd
CY2022	us-gaap	Revenues Revenues	969783	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	302037	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	286415	usd
CY2023	us-gaap	Gross Profit GrossProfit	-149607	usd
CY2022	us-gaap	Gross Profit GrossProfit	683368	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5368278	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6067545	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1062916	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2693457	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1635708	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	7036778	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	8066902	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	15797780	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-8216509	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-15114412	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	185481	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	187817	usd
CY2023	us-gaap	Interest Expense InterestExpense	2493340	usd
CY2022	us-gaap	Interest Expense InterestExpense	293968	usd
CY2023	abvc	Operating Sublease Income OperatingSubleaseIncome	65900	usd
CY2022	abvc	Operating Sublease Income OperatingSubleaseIncome	107150	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	110125	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-7446	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	22690	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-259463	usd
CY2023	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-221888	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3384	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-24149	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2437773	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-400184	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10654282	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15514596	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	256006	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	797778	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-10910288	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-16312374	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-394632	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	110865	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-10515656	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16423239	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-741	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-22532	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10516397	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16445771	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.43
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.19
CY2023	us-gaap	Profit Loss ProfitLoss	-10910288	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-16312374	usd
CY2023	us-gaap	Depreciation Depreciation	28531	usd
CY2022	us-gaap	Depreciation Depreciation	23799	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1635708	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	7036778	usd
CY2022	abvc	Inventory Allowance For Valuation Losses InventoryAllowanceForValuationLosses	25975	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1455101	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	184589	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2413746	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-32350	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	110125	usd
CY2023	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-221888	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	115668	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	864802	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-228557	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	614166	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-101926	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-238092	usd
CY2023	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	321776	usd
CY2022	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	837014	usd
CY2023	abvc	Common Shares Issued For Debt Conversion CommonSharesIssuedForDebtConversion	786793	usd
CY2022	abvc	Common Shares Issued For Debt Conversion CommonSharesIssuedForDebtConversion	1608784	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	68515	usd
CY2023	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	13700	usd
CY2022	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-2600	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	112946	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-186860	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	242469	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4235845	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7398391	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	21201	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	119692	usd
CY2023	abvc	Prepayment For Equity Investments PrepaymentForEquityInvestments	338985	usd
CY2022	abvc	Prepayment For Equity Investments PrepaymentForEquityInvestments	1601992	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-360186	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1721684	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1050000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3663925	usd
CY2023	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1000000	usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2406338	usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	350000	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1462622	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3918960	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4013925	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2123	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-67337	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-674948	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5173487	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1391728	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6565215	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	716780	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1391728	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	33180	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	285465	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	27392	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	1600	usd
CY2023	abvc	Purchase Of Property And Equipment By Issuing Common Stock To A Third Party PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty	7400000	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	3306112	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8870342	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3663925	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4891888	usd
CY2022	abvc	Stockbased Compensation For Services StockbasedCompensationForServices	902960	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1241930	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-16312374	usd
CY2022	abvc	Cumulative Transaction Adjustments CumulativeTransactionAdjustments	-22532	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3236139	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1050000	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	732748	usd
CY2023	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	7400000	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3306112	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1706338	usd
CY2023	abvc	Issuance Of Prefunded Warrant IssuanceOfPrefundedWarrant	700000	usd
CY2023	abvc	Stockbased Compensation For Services StockbasedCompensationForServices	902960	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-10910288	usd
CY2023	abvc	Cumulative Transaction Adjustments CumulativeTransactionAdjustments	-741	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	7704	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8130972	usd
CY2023Q4	us-gaap	Royalty Expense RoyaltyExpense	3500000	usd
CY2023Q4	abvc	Royalties Percentage royaltiesPercentage	0.05	pure
CY2023Q4	us-gaap	Excise And Sales Taxes ExciseAndSalesTaxes	100000000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-10910288	usd
CY2023Q4	abvc	Working Capital Deficit WorkingCapitalDeficit	-4275781	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4235845	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Reclassifications of Prior Year Presentation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior year unaudited consolidated balance sheet and unaudited consolidated cash flow statement amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</p>
CY2023	us-gaap	Fiscal Period FiscalPeriod	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Fiscal Year</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. </p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> </p>
CY2023Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On July 25, 2023, the Company filed a Certificate of Amendment to its Articles of Incorporation authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its common stock.
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation’s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We perform ongoing credit evaluation of our customers and requires no collateral. An allowance for doubtful accounts is provided based on a review of the collectability of accounts receivable. We determine the amount of allowance for doubtful accounts by examining its historical collection experience and current trends in the credit quality of its customers as well as its internal credit policies. Actual credit losses may differ from our estimates.</p>
CY2023	us-gaap	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivable	0.8724	pure
CY2022Q4	abvc	Total Account Receivable Percentage TotalAccountReceivablePercentage	0.7189	pure
CY2023	abvc	Total Revenues Percentage TotalRevenuesPercentage	0.8004	pure
CY2022	abvc	Total Revenues Percentage TotalRevenuesPercentage	0.9322	pure
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60155	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85265	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	656625	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	1306463	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	37000000	usd
CY2023	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	7400000	usd
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	370000	shares
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	616505	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	194957	usd
CY2023	abvc	Impairment Of Equity Investments ImpairmentOfEquityInvestments	0	usd
CY2022	abvc	Impairment Of Equity Investments ImpairmentOfEquityInvestments	0	usd
CY2023Q4	us-gaap	Regulatory Asset Amortization Period RegulatoryAssetAmortizationPeriod	P18Y
CY2023	abvc	Labor Pension Fund Per Month LaborPensionFundPerMonth	0.06	pure
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06	pure
CY2022Q4	us-gaap	Accrued Employee Benefits Current And Noncurrent AccruedEmployeeBenefitsCurrentAndNoncurrent	10314	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current And Noncurrent AccruedEmployeeBenefitsCurrentAndNoncurrent	13031	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	0	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1241930	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	1635708	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	5794848	usd
CY2023	abvc	Defined Benefit Plan Funded Percentages DefinedBenefitPlanFundedPercentages	0.50	pure
CY2023	abvc	Milestone Payments Royalty Percentage MilestonePaymentsRoyaltyPercentage	0.12	pure
CY2015	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	50000000	twd
CY2015Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	1600000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	100000000	usd
CY2023	abvc	Percentage Of Net Sales PercentageOfNetSales	0.05	pure
CY2023	abvc	Agreement Percentage AgreementPercentage	0.15	pure
CY2021	abvc	Agreement Percentage AgreementPercentage	0.05	pure
CY2022	abvc	Agreement Percentage AgreementPercentage	0.10	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	5000000	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	50
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1.6
CY2018Q4	abvc	Equity Method Long Term Investment EquityMethodLongTermInvestment	1530000	shares
CY2018	us-gaap	Gain Loss On Investments GainLossOnInvestments	549	usd
CY2022Q2	abvc	Service Agreement Eligibility Amount ServiceAgreementEligibilityAmount	3000000	usd
CY2022Q2	abvc	Milestone Regulatory Payment Amount Period MilestoneRegulatoryPaymentAmountPeriod	P3Y
CY2023Q4	us-gaap	Loans Payable LoansPayable	1000000	usd
CY2023	abvc	Working Capital Convertible Loan Percentage WorkingCapitalConvertibleLoanPercentage	0.05	pure
CY2023	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	The Company may convert the Note at any time into shares of Rgene’s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note.
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11304319	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3878435	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3335041	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3304457	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7969278	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	573978	usd
CY2023Q4	us-gaap	Share Price SharePrice	20
CY2023	us-gaap	Depreciation Depreciation	28531	usd
CY2022	us-gaap	Depreciation Depreciation	23799	usd
CY2023	abvc	Schedule Of Ownership Percentages Of Investee Table Text Blocks ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks	<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ownership percentages of each investee are listed as follows:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ownership percentage</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: center">Accounting</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name of related party</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">treatments</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Braingenesis Biotechnology Co., Ltd.</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.17</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.17</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Genepharm Biotech Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.67</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.67</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">BioHopeKing Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.90</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.90</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Cost Method</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">BioFirst Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18.68</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15.51</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Equity Method</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rgene Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26.65</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26.65</td><td style="text-align: left">%</td><td> </td> <td style="text-align: center">Equity Method</td></tr> </table>
CY2023Q4	abvc	Nonmarketable Cost Method Investments Net NonmarketableCostMethodInvestmentsNet	847252	usd
CY2022Q4	abvc	Nonmarketable Cost Method Investments Net NonmarketableCostMethodInvestmentsNet	842070	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	2527740	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	842070	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	2688578	usd
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1895556	usd
CY2023	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	994450	shares
CY2023	abvc	Percentage Common Stocks Shares PercentageCommonStocksShares	0.2665	pure
CY2022	abvc	Percentage Common Stocks Shares PercentageCommonStocksShares	0.2665	pure
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	899250	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-221888	usd
CY2023Q1	abvc	Purchase Warrant Term PurchaseWarrantTerm	P5Y
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1225543	usd
CY2023	abvc	Percentage Of Cash Permium PercentageOfCashPermium	0.05	pure
CY2023Q3	abvc	Percentage Of Outstanding Principal Amount PercentageOfOutstandingPrincipalAmount	1.15	pure
CY2023Q3	us-gaap	General Partners Capital Account GeneralPartnersCapitalAccount	12500000	usd
CY2023Q4	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	3.5
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1200000	usd
CY2023Q4	abvc	Purchase Warrant Term PurchaseWarrantTerm	P5Y
CY2023Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	480795	usd
CY2023Q4	abvc	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1799583	usd
CY2022Q4	abvc	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1600221	usd
CY2023Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	1184505	usd
CY2022Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	568865	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	274028	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	272352	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	438264	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	468150	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3696380	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2909587	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	1893750	usd
CY2020Q2	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	350000	usd
CY2020Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	350000	usd
CY2021Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	650000	usd
CY2022	us-gaap	Shortterm Debt Average Outstanding Amount ShorttermDebtAverageOutstandingAmount	1000000	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	10463	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	757343	usd
CY2023	abvc	Revenue From Related Party RevenueFromRelatedParty	2055	usd
CY2022	abvc	Revenue From Related Party RevenueFromRelatedParty	904043	usd
CY2023Q4	us-gaap	Other Receivable Before Allowance For Credit Loss Noncurrent OtherReceivableBeforeAllowanceForCreditLossNoncurrent	953499	usd
CY2022Q4	us-gaap	Other Receivable Before Allowance For Credit Loss Noncurrent OtherReceivableBeforeAllowanceForCreditLossNoncurrent	865477	usd
CY2023Q4	us-gaap	Other Receivable Allowance For Credit Loss Noncurrent OtherReceivableAllowanceForCreditLossNoncurrent	839983	usd
CY2023Q4	us-gaap	Other Receivable After Allowance For Credit Loss Noncurrent OtherReceivableAfterAllowanceForCreditLossNoncurrent	113516	usd
CY2022Q4	us-gaap	Other Receivable After Allowance For Credit Loss Noncurrent OtherReceivableAfterAllowanceForCreditLossNoncurrent	865477	usd
CY2022Q2	us-gaap	Accounts Payable Interest Bearing Interest Rate AccountsPayableInterestBearingInterestRate	0.05	pure
CY2022Q2	abvc	Working Capital Percentage WorkingCapitalPercentage	0.064	pure
CY2023	abvc	Description Of Conversion Price DescriptionOfConversionPrice	The Company may convert the Note at any time into shares of Rgene’s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross-default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided.
CY2023Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	38819	usd
CY2022Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	13819	usd
CY2022Q4	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	507000	usd
CY2023Q4	us-gaap	Derivative Fixed Interest Rate DerivativeFixedInterestRate	0.065	pure
CY2023	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	113516	usd
CY2022	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	112822	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	173132	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	359992	usd
CY2022	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	188753	usd
CY2023	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	147875	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	40878	usd
CY2023Q4	abvc	Outstanding Principal And Accrued Interests OutstandingPrincipalAndAccruedInterests	152382	usd
CY2022Q4	abvc	Outstanding Principal And Accrued Interests OutstandingPrincipalAndAccruedInterests	151450	usd
CY2023	us-gaap	Interest And Debt Expense InterestAndDebtExpense	20094	usd
CY2022	us-gaap	Interest And Debt Expense InterestAndDebtExpense	21378	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2400	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	140338	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	140338	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2400	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	115668	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	795378	usd
CY2023	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	115668	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	795378	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	256006	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	797778	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	713223	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	709961	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	5568391	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	5866623	usd
CY2023Q4	abvc	Operating Lease Liabilities OperatingLeaseLiabilities	213482	usd
CY2022Q4	abvc	Operating Lease Liabilities OperatingLeaseLiabilities	213482	usd
CY2023Q4	abvc	Deferred Tax Assets Operating Lease Assets DeferredTaxAssetsOperatingLeaseAssets	-213482	usd
CY2022Q4	abvc	Deferred Tax Assets Operating Lease Assets DeferredTaxAssetsOperatingLeaseAssets	-213482	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	6281614	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	6576584	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6281614	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6459474	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	117110	usd
CY2022Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	4296763	usd
CY2022Q1	abvc	Unrestricted Common Shares UnrestrictedCommonShares	1306007	shares
CY2022Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	3.29
CY2022Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2000000	shares
CY2022Q2	us-gaap	Legal Fees LegalFees	556075	usd
CY2022Q2	us-gaap	Credit Derivative Term1 CreditDerivativeTerm1	P5Y
CY2022Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	2000000	shares
CY2022Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	2.45	shares
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	3704167	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1225543	usd
CY2023Q4	us-gaap	Investment Sold Not Yet Purchased Balance Shares InvestmentSoldNotYetPurchasedBalanceShares	3732167	shares
CY2023Q4	us-gaap	Investment Sold Not Yet Purchased Balance Principal Amount InvestmentSoldNotYetPurchasedBalancePrincipalAmount	3306112	usd
CY2023Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	300000	shares
CY2023Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	3.5
CY2023	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	29600	shares
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1200000	usd
CY2023Q4	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	1000000	usd
CY2023Q4	us-gaap	Common Stock Convertible Conversion Price Decrease CommonStockConvertibleConversionPriceDecrease	3.5
CY2023Q4	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.90	pure
CY2023Q4	abvc	Purchase Warrant Term PurchaseWarrantTerm	P5Y
CY2023Q4	us-gaap	Credit Derivative Term1 CreditDerivativeTerm1	P5Y
CY2023Q4	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	1000000	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2
CY2023Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	480795	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	545182	shares
CY2020Q4	abvc	Conversion Price Per Share ConversionPricePerShare	2
CY2020Q4	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1090361	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	545182	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2021Q4	abvc	Number Of Directors NumberOfDirectors	11	pure
CY2021Q4	abvc	Number Of Employees NumberOfEmployees	3	pure
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2022Q2	abvc	Number Of Directors NumberOfDirectors	5	pure
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2587104	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.79
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M26D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2587104	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.79
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M26D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2587104	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.79
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y8M26D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2587104	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.79
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y8M26D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0279	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8386	pure
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	0	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	761920	shares
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	0	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1241930	usd
CY2023Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P5Y
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	809283	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1161141	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	401826	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	369314	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	407457	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	791827	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	358576	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	358576	usd
CY2023	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	385659	usd
CY2022	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	358576	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M23D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y5M23D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.015	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0149	pure
CY2023Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	404745	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	351352	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	56916	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	813013	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3730	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	809283	usd
CY2023Q4	abvc	Shares Received SharesReceived	23000000	shares
CY2023Q4	us-gaap	Royalty Expense RoyaltyExpense	3500000	usd
CY2023Q4	abvc	Royalties Percentage royaltiesPercentage	0.05	pure
CY2023Q4	us-gaap	Excise And Sales Taxes ExciseAndSalesTaxes	100000000	usd
CY2023Q4	abvc	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Expense And Other Current Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities	243888	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Long Term Debt BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt	498	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	243386	usd
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
CY2022	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss		usd
CY2023	abvc	Inventory Allowance For Valuation Losses InventoryAllowanceForValuationLosses		usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2022	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss		usd
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt		usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2023	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2022	abvc	Purchase Of Property And Equipment By Issuing Common Stock To A Third Party PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards		usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards		usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents		usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets		usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001173313

Files In Submission

Name	View Source	Status
0001213900-24-022235-index-headers.html	Edgar Link	pending
0001213900-24-022235-index.html	Edgar Link	pending
0001213900-24-022235.txt	Edgar Link	pending
0001213900-24-022235-xbrl.zip	Edgar Link	pending
abvc-20231231.xsd	Edgar Link	pending
ea0201142-10k_abvcbio.htm	Edgar Link	pending
ea0201142ex21-1_abvcbiophar.htm	Edgar Link	pending
ea0201142ex31-1_abvcbiophar.htm	Edgar Link	pending
ea0201142ex31-2_abvcbiophar.htm	Edgar Link	pending
ea0201142ex32-1_abvcbiophar.htm	Edgar Link	pending
ea0201142ex32-2_abvcbiophar.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
abvc-20231231_cal.xml	Edgar Link	unprocessable
abvc-20231231_def.xml	Edgar Link	unprocessable
abvc-20231231_lab.xml	Edgar Link	unprocessable
abvc-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0201142-10k_abvcbio_htm.xml	Edgar Link	completed
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABVC
ABVC BIOPHARMA, INC. Stock $abvc

2024 Q1 Form 10-K Financial Statement

#000121390024022235 Filed on March 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABVC ABVC BIOPHARMA, INC. Stock $abvc

2024 Q1 Form 10-K Financial Statement

#000121390024022235 Filed on March 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABVC
ABVC BIOPHARMA, INC. Stock $abvc